Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.

ABSTRACT:

Background

Rituximab has been shown to improve response rates and progression free survival when added to chemotherapy in patients with indolent and mantle cell lymphoma. However, the impact of R on overall survival (OS) when given in combination with chemotherapy (R-chemo) has remained unclear so far.

Objectives

We thus performed a comprehensive systematic review in this group of patients to compare R-chemo with chemotherapy alone with respect to OS. Other endpoints were overall response rate (ORR), toxicity and disease control as assessed by measures such as time to treatment failure (TTF), event free-survival (EFS), progression free-survival (PFS) and time to progression (TTP).

Search strategy

We searched the Cochrane Central Register of Controlled Trials (CENTRAL)

SUBMITTER: Schulz H 

PROVIDER: S-EPMC9017066 | biostudies-literature | 2007 Oct

REPOSITORIES: biostudies-literature